Meet with Inoviv at
ALS Drug Discovery Summit
Conference Details
Date: May 21 – 23, 2024
Meet us at Booth #7
Location: Boston, MA
About the Conference
Don’t miss this opportunity to stay informed, engage with 150+ industry leaders, and shape the future of ALS drug development at the 3rd Annual ALS Drug Development Summit. Returning to Boston to provide a comprehensive breakdown of the latest motor neuron models, biomarker strategies, approval insights, and novel approaches to target the likes of TDP-43, STMN2, and PIKfyve. Engage in forward-thinking discussions and gain fresh perspectives on the most meaningful endpoints and trial design considerations for people living with ALS.
Meet us at Booth #7 to discuss the following:
Our mission is to generate novel molecular insights that transform drug development and healthcare globally.
We deliver multiplexed & quantitative LC-MS proteomics with end-to-end support.
Generating Insights that Matter through LC-MS-based Proteomics
LC-MS workflows provide clinical grade measurement and absolute quantification down to pg/mL of proteins that are required for regulatory submission
Ability to identify multiple epitopes (peptides) per protein to achieve high confidence/high coverage data and insights into lipids, metabolites, and more to support multi-omic analysis
Validated, Versatile, & Adaptable Analysis with LC-MS Assays
Can be adapted to provide definitive data into post-translational modifications, other proteins, lipids, and metabolites
Suitable for almost any sample type, including blood plasma/serum, cerebrospinal fluid, urine, FFPE, or fresh frozen tissue.
Analytical Validation to Accelerate Clinical Trial Workflows
Following the FDA Bioanalytical Method Validation guidelines for data submission
CLIA, FDA inspected (US) and GCP/GLP (UK) certified labs
Our proprietary analytical algorithms, workflows, and internal standards provide the highest possible reproducibility and robustness across thousands of samples with a linear dynamic range over six orders of magnitude.
